Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure
4 institutional releases
Published in JAMA · View the paper (DOI)
A randomized clinical trial found that avoiding aspirin as part of an antithrombotic regimen reduces bleeding events without increasing thromboembolism risk in patients with advanced heart failure treated with left ventricular assist devices. The study suggests that aspirin avoidance may be a viable option for these patients.
Coverage from 4 institutions
- Aspirin and hemocompatibility events with a left ventricular assist device in advanced heart failure JAMA Network · Nov 11, 2023 · first to report
- Researchers find aspirin avoidance is safe for patients with modern heart pumps Brigham and Women's Hospital · Nov 14, 2023
- Ochsner participates in study showing aspirin may not be necessary with LVAD Ochsner Health System · Nov 20, 2023
- Novel study finds aspirin-free regimen benefits patients with LVAD University of North Carolina Health Care · Nov 29, 2023